Skip to main content

Table 1 Patient characteristics and surgical characteristics of first single pulmonary metastasectomy (PM)

From: Survival prognostic and recurrence risk factors after single pulmonary metastasectomy

Single PM

162

Sex

 

 Female

72 (44.4%)

 Male

90 (55.6%)

Age (median)

64 [IQR 55–71]

Comorbidities

 

 Cardiopathy

12 (7.4%)

 High blood pressure

61 (37.7%)

 Pulmonary disease

13 (8%)

 Tobacco exposure

49 (30.3%)

 Diabetes

23 (14.2%)

 Renal failure

11 (6.8%)

 Immunosuppression

6 (3.7%)

Primary tumour

 

 Colorectal

51 (31.5%)

 Melanoma

33 (20.4%)

 Sarcoma

24 (14.8%)

 Other

54 (33.3%)

Pulmonary metastasis

 

 Size [mm] (median)

10.5 [7–16]

 Margins [mm] (median)

6 [3–12]

 R0

159 (98.2%)

 R1

3 (1.9%)

 Lymph node involvement

9 (5.6%)

First PM

 

 VATS

136 (83.9%)

 Thoracotomy

26 (16.1%)

 Wedge resection

119 (73.5%)

 Segmentectomy

12 (7.4%)

 Lobectomy

29 (17.9%)

 Pneumonectomy

2 (1.2%)

 Mediastinal lymph nodes dissection

36 (22.2%)

Post-operative outcomes

 

 Overall 30-d mortality

0

 Overall 30-d morbidity

19 (11.7%)

  Pulmonary complications

12 (7.4%)

  Cardiac complications

3 (1.9%)

 Duration of drainage [days] (median)

1 [IQR 1–2]

 Duration of hospital stay [days] (median)

4 [IQR 3–7]

 Readmission (30-d)

2 (1.2%)

 Re-operation (30-d)

1 (0.6%)

  1. PM pulmonary metastasectomy, cardiopathy (defined as the presence of ischemic events in the past, cardiac insufficiency, arrhythmia or aortic aneurysm), high blood pressure (defined as systolic arterial pressure > 140 mmHg), pulmonary disease (defined as the presence of chronic obstructive pulmonary disease, fibrosis, pulmonary hypertension or sleep apnoea syndrome), diabetes (defined as fasting plasma glucose > 7 mmol/l), renal failure (defined as glomerular filtration rate < 30 ml/min/1.73 m2). R0 (defined as the absence of cancer cells seen microscopically at the tumor site), R1 (defined as the presence of cancer cells microscopically at the tumor site), R2 (defined as macroscopic residual tumor at cancer site or regional lymph nodes)